Silo Pharma Inc (SILO) - Total Liabilities
Based on the latest financial reports, Silo Pharma Inc (SILO) has total liabilities worth $1.07 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Silo Pharma Inc to see how much of total assets are deployed in long-term investments.
Silo Pharma Inc - Total Liabilities Trend (2010–2025)
This chart illustrates how Silo Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Silo Pharma Inc balance sheet assets.
Silo Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Silo Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Crown Capital Partners Inc
TO:CRWN
|
Canada | CA$132.35 Million |
|
Madhav Marbles and Granites Limited
NSE:MADHAV
|
India | Rs190.93 Million |
|
BioNexus Gene Lab Corp Common stock
NASDAQ:BGLC
|
USA | $804.97K |
|
Cerebra Integrated Technologies Limited
NSE:CEREBRAINT
|
India | Rs-910.55 Million |
|
Vaxtex Cotfab Limited
NSE:VCL
|
India | Rs143.82 Million |
|
Australian Silica Quartz Group Ltd
AU:ASQ
|
Australia | AU$100.91K |
|
NIOX Group PLC
LSE:NIOX
|
UK | GBX8.60 Million |
|
Mustang Bio Inc
NASDAQ:MBIO
|
USA | $8.07 Million |
Liability Composition Analysis (2010–2025)
This chart breaks down Silo Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Silo Pharma Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Silo Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Silo Pharma Inc (2010–2025)
The table below shows the annual total liabilities of Silo Pharma Inc from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.30 Million | -45.34% |
| 2024-12-31 | $2.38 Million | +51.51% |
| 2023-12-31 | $1.57 Million | +20.52% |
| 2022-12-31 | $1.30 Million | -8.81% |
| 2021-12-31 | $1.43 Million | +878.24% |
| 2020-12-31 | $145.97K | -71.75% |
| 2019-12-31 | $516.74K | +15.35% |
| 2018-12-31 | $447.98K | +2.20% |
| 2017-12-31 | $438.34K | -3.26% |
| 2016-12-31 | $453.10K | -7.67% |
| 2015-12-31 | $490.76K | +21.91% |
| 2014-12-31 | $402.56K | -3.86% |
| 2013-12-31 | $418.72K | +909.61% |
| 2012-12-31 | $41.47K | +1084.94% |
| 2011-12-31 | $3.50K | -107.37% |
| 2010-12-31 | $-47.48K | -- |
About Silo Pharma Inc
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's… Read more